Scarica l'app Stockscreener
1.585
1.57%
-0.005
Precedente Chiudi:
$1.59
Aprire:
$1.6
Volume 24 ore:
236.63K
Relative Volume:
0.42
Capitalizzazione di mercato:
$189.38M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-4.1843
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
+0.32%
1M Prestazione:
+39.73%
6M Prestazione:
-60.48%
1 anno Prestazione:
-20.96%
Intervallo 1D:
$1.52
$1.61
Intervallo di 1 settimana:
$1.47
$1.70
Portata 52W:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PRQR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.58 | 189.38M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.00 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
543.60 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.45 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.31 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating - marketscreener.com
ProQR (PRQR) Price Target Cut by Oppenheimer Amid Clinical Updates | PRQR Stock News - GuruFocus
DAFNA Capital Management LLC Has $4.15 Million Stake in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - Yahoo Finance
Raymond James Financial Inc. Invests $260,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Analysts - Defense World
ProQR: Q1 Earnings Snapshot - News-Times
1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR) - simplywall.st
ProQR Therapeutics NV earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ProQR Therapeutics NV earnings missed, revenue topped estimates - Investing.com
ProQR (PRQR) Reports Q1 Revenue Growth and Strategic Milestones - GuruFocus
ProQR Reports Q1 2025 Financial Results Amid Rising R&D Costs - TipRanks
ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position - Nasdaq
ProQR Announces First Quarter 2025 Operating and Financial Results - GlobeNewswire
ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday - MarketBeat
Invesco Ltd. Purchases Shares of 11,887 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Issue Forecasts for PRQR FY2025 Earnings - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Boothbay Fund Management LLC - MarketBeat
ProQR Therapeutics N.V (NASDAQ: PRQR) Posted 2.58% Gain This Year: What’s Next? - Stocksregister
JPMorgan Chase & Co. Has $142,000 Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Evercore ISI Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
ProQR Therapeutics NV expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ProQR Announces Webcast of Presentation at the 2025 Citizens Lif - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference | PRQR Stock News - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference - GlobeNewswire
RNA Editing Pioneer ProQR to Showcase Breakthrough Axiomer Platform at Major Healthcare Conference - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Earns Outperform Rating from Analysts at Evercore ISI - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Research Coverage Started at Cantor Fitzgerald - Defense World
Adage Capital Partners GP L.L.C. Purchases 5,976,813 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 - The Manila Times
ProQR Therapeutics N.V [PRQR] Investment Appeal on the Rise - knoxdaily.com
RNA Editing Market Deep Research 2025-2032 | QIAGEN N.V., ProQR - openPR.com
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - Nasdaq
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
ProQR Therapeutics initiated with an Outperform at Evercore ISI - Yahoo Finance
XTX Topco Ltd Takes $163,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - The AM Reporter
Riding the Waves: A Guide to Investing in PRQR Stock - investchronicle.com
Evercore ISI sets ProQR stock Outperform with $5 target By Investing.com - Investing.com India
ProQR Therapeutics (PRQR) Receives Overweight Rating and $8 Pric - GuruFocus
Cantor Fitzgerald sets $8 price target on ProQR shares with Overweight rating - Investing.com
ProQR Therapeutics (PRQR) Gains Outperform Rating from Evercore ISI | PRQR Stock News - GuruFocus
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.19%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):